Literature DB >> 10521296

The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events.

J C Moolman-Smook1, W J De Lange, E C Bruwer, P A Brink, V A Corfield.   

Abstract

Hypertrophic cardiomyopathy (HCM) is an autosomal dominantly inherited disease of the cardiac sarcomere, caused by numerous mutations in genes encoding protein components of this structure. Mutation carriers are at risk of sudden cardiac death, mostly as adolescents or young adults. The reproductive disadvantage incurred may explain both the global occurrence of diverse independent HCM-associated mutations and the rare reports of founder effects within populations. We have investigated whether this holds true for two South African subpopulations, one of mixed ancestry and one of northern-European descent. Previously, we had detected three novel mutations-Ala797Thr in the beta-myosin heavy-chain gene (betaMHC), Arg92Trp in the cardiac troponin T gene (cTnT), and Arg645His in the myosin-binding protein C gene (MyBPC)-and two documented betaMHC mutations (Arg403Trp and Arg249Gln). Here we report three additional novel mutations-Gln499Lys in betaMHC and Val896Met and Deltac756 in MyBPC-and the documented betaMHC Arg719Gln mutation. Seven of the nine HCM-causing mutations arose independently; no conclusions can be drawn for the remaining two. However, the betaMHC Arg403Trp and Ala797Thr and cTnT Arg92Trp mutations were detected in another one, eight, and four probands, respectively, and haplotype analysis in families carrying these recurring mutations inferred their origin from three common ancestors. The milder phenotype of the betaMHC mutations may account for the presence of these founder effects, whereas population dynamics alone may have overridden the reproductive disadvantage incurred by the more lethal, cTnT Arg92Trp mutation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521296      PMCID: PMC1288283          DOI: 10.1086/302623

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

1.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy.

Authors:  L Carrier; G Bonne; E Bährend; B Yu; P Richard; F Niel; B Hainque; C Cruaud; F Gary; S Labeit; J B Bouhour; O Dubourg; M Desnos; A A Hagège; R J Trent; M Komajda; M Fiszman; K Schwartz
Journal:  Circ Res       Date:  1997-03       Impact factor: 17.367

2.  Evidence of a long QT founder gene with varying phenotypic expression in South African families.

Authors:  T de Jager; C H Corbett; J C Badenhorst; P A Brink; V A Corfield
Journal:  J Med Genet       Date:  1996-07       Impact factor: 6.318

3.  Identification of a novel Ala797Thr mutation in exon 21 of the beta-myosin heavy chain gene in hypertrophic cardiomyopathy.

Authors:  J C Moolman; P A Brink; V A Corfield
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

4.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

Authors:  B J Maron; J M Gardin; J M Flack; S S Gidding; T T Kurosaki; D E Bild
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

5.  Identification of three mutations and associated haplotypes in the protoporphyrinogen oxidase gene in South African families with variegate porphyria.

Authors:  L Warnich; M J Kotze; I M Groenewald; J Z Groenewald; M G van Brakel; C J van Heerden; J N de Villiers; W J van de Ven; E F Schoenmakers; S Taketani; A E Retief
Journal:  Hum Mol Genet       Date:  1996-07       Impact factor: 6.150

6.  Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations.

Authors:  B M Posen; J C Moolman; V A Corfield; P A Brink
Journal:  Br Heart J       Date:  1995-07

7.  A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3.

Authors:  H Watkins; C MacRae; L Thierfelder; Y H Chou; M Frenneaux; W McKenna; J G Seidman; C E Seidman
Journal:  Nat Genet       Date:  1993-04       Impact factor: 38.330

8.  Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy.

Authors:  I Rayment; H M Holden; J R Sellers; L Fananapazir; N D Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

Review 9.  Contractile protein mutations and heart disease.

Authors:  K L Vikstrom; L A Leinwand
Journal:  Curr Opin Cell Biol       Date:  1996-02       Impact factor: 8.382

10.  A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy.

Authors:  A Freiburg; M Gautel
Journal:  Eur J Biochem       Date:  1996-01-15
View more
  27 in total

1.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

Review 2.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

3.  Of founder populations, long QT syndrome, and destiny.

Authors:  Paul A Brink; Peter J Schwartz
Journal:  Heart Rhythm       Date:  2009-09-03       Impact factor: 6.343

4.  Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.

Authors:  Christopher N Toepfer; Hiroko Wakimoto; Amanda C Garfinkel; Barbara McDonough; Dan Liao; Jianming Jiang; Angela C Tai; Joshua M Gorham; Ida G Lunde; Mingyue Lun; Thomas L Lynch; James W McNamara; Sakthivel Sadayappan; Charles S Redwood; Hugh C Watkins; Jonathan G Seidman; Christine E Seidman
Journal:  Sci Transl Med       Date:  2019-01-23       Impact factor: 17.956

5.  Cryo-EM structure of a human cytoplasmic actomyosin complex at near-atomic resolution.

Authors:  Julian von der Ecken; Sarah M Heissler; Salma Pathan-Chhatbar; Dietmar J Manstein; Stefan Raunser
Journal:  Nature       Date:  2016-06-20       Impact factor: 49.962

Review 6.  Genetics of inherited cardiomyopathies in Africa.

Authors:  Gasnat Shaboodien; Timothy F Spracklen; Stephen Kamuli; Polycarp Ndibangwi; Carla Van Niekerk; Ntobeko A B Ntusi
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

7.  Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy.

Authors:  Lize van der Merwe; Ruben Cloete; Miriam Revera; Marshall Heradien; Althea Goosen; Valerie A Corfield; Paul A Brink; Johanna C Moolman-Smook
Journal:  Hum Genet       Date:  2008-06-17       Impact factor: 4.132

8.  Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations.

Authors:  Marshall Heradien; Miriam Revera; Lize van der Merwe; Althea Goosen; Valerie A Corfield; Paul A Brink; Bongani M Mayosi; Johanna C Moolman-Smook
Journal:  Heart Rhythm       Date:  2009-09-01       Impact factor: 6.343

9.  Serial observations and mutational analysis of an adoptee with family history of hypertrophic cardiomyopathy.

Authors:  Bronwyn Harris; Jean P Pfotenhauer; Cheri A Silverstein; Larry W Markham; Kim Schafer; Vernat J Exil; Charles C Hong
Journal:  Cardiol Res Pract       Date:  2010-03-11       Impact factor: 1.866

10.  MYBPC3 Haplotype Linked to Hypertrophic Cardiomyopathy in Rhesus Macaques (Macaca mulatta).

Authors:  Robert F Oldt; Kimberly J Bussey; Matthew L Settles; Joseph N Fass; Jeffrey A Roberts; J Rachel Reader; Srivathsan Komandoor; Victor A Abrich; Sreetharan Kanthaswamy
Journal:  Comp Med       Date:  2020-08-04       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.